-
Journal of Clinical Ultrasound : JCU Oct 2022Aortic regurgitation (AR) is a common valvular pathology. Multimodality noninvasive cardiovascular imaging is routinely used to assess the mechanism of AR, degree, and... (Review)
Review
Aortic regurgitation (AR) is a common valvular pathology. Multimodality noninvasive cardiovascular imaging is routinely used to assess the mechanism of AR, degree, and its hemodynamic impact on the cardiovascular system. Collecting this information is crucial in establishing the prognosis and in guiding patient management and follow-up. While echocardiography remains the primary test to assess AR, a comprehensive assessment of this valvulopathy can be obtained by combining the information from different techniques. This state-of-the-art review is intended to provide an update ed overview of the applications, strengths, and limits of transthoracic echocardiography, cardiac magnetic resonance, and cardiac computed tomography in patients with AR.
Topics: Aortic Valve Insufficiency; Echocardiography; Heart Valve Diseases; Humans; Magnetic Resonance Imaging; Multimodal Imaging
PubMed: 36218214
DOI: 10.1002/jcu.23299 -
Circulation Jul 2020
Topics: Cardiovascular Diseases; Disease Management; Echocardiography; Humans; Mass Screening; Multimodal Imaging; Practice Guidelines as Topic
PubMed: 32687444
DOI: 10.1161/CIR.0000000000000764 -
Lung Apr 2020Acute pulmonary embolism (PE) is a leading cause of cardiovascular morbidity. The most common long-term complication of acute PE is chronic thromboembolic disease, a... (Review)
Review
Acute pulmonary embolism (PE) is a leading cause of cardiovascular morbidity. The most common long-term complication of acute PE is chronic thromboembolic disease, a heterogenous entity which ranges from asymptomatic imaging sequelae to persistent symptoms. Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease that can develop in this population and represents the only treatable type of pulmonary hypertension. Recognition of the characteristic findings of chronic pulmonary embolism and CTEPH provides not only diagnostic information, but is also crucial for guiding therapy. The present state-of-the-art review focuses on the multimodality imaging features of chronic pulmonary embolism. Detailed description and illustrations of relevant imaging findings will be demonstrated for ventilation/perfusion (V/Q) scan, CT scan and Dual-Energy CT and MRI and features that distinguish chronic PE from common imaging mimics.
Topics: Diagnosis, Differential; Humans; Hypertension, Pulmonary; Lung; Multimodal Imaging; Pulmonary Embolism
PubMed: 32166427
DOI: 10.1007/s00408-020-00344-3 -
Der Radiologe May 2020
Topics: Coronary Angiography; Humans; Multimodal Imaging; Radiologists
PubMed: 32342152
DOI: 10.1007/s00117-020-00677-3 -
Seminars in Nuclear Medicine May 2021Since many years, magnetic resonance imaging (MRI) and positron emission tomography (PET) have a prominent role in neurodegenerative disorders and dementia, not only in... (Review)
Review
Since many years, magnetic resonance imaging (MRI) and positron emission tomography (PET) have a prominent role in neurodegenerative disorders and dementia, not only in a research setting but also in a clinical setting. For several decades, information from both modalities is combined ranging from individual visual assessments to fully integrating all images. Several tools are available to coregister images from MRI and PET and to covisualize these images. When studying neurodegenerative disorders with PET it is important to perform a partial volume correction and this can be done using the structural information obtained by MRI. With the advent of PET/MR, the question arises in how far this hybrid imaging modality is an added value compared to combining PET and MRI data from two separate modalities. One issue in PET/MR is still not yet completely settled, that is, the attenuation correction. This is of less importance for visual assessments but it can become an issue when combining data from PET/CT and PET/MR scanners in multicenter studies or when using cut-off values to classify patients. Simultaneous imaging has clearly some advantages: for the patient it is beneficial to have only one scan session instead of two but also in cases in which PET data are related to functional of physiological data acquired with MRI (such as functional MRI or arterial spin labeling). However, the most important benefit is currently the more integrated use of PET and MRI. This is also possible with separate measurements but requires more streamlining of the whole process. In that case coregistration of images is mandatory. It needs to be determined in which cases simultaneous PET/MRI leads to new insights or improved diagnosis compared to multimodal imaging using dedicated scanners.
Topics: Dementia; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography
PubMed: 33526230
DOI: 10.1053/j.semnuclmed.2021.01.003 -
Chemical Society Reviews Jun 2024Optoacoustic (OA) imaging offers powerful capabilities for interrogating biological tissues with rich optical absorption contrast while maintaining high spatial... (Review)
Review
Optoacoustic (OA) imaging offers powerful capabilities for interrogating biological tissues with rich optical absorption contrast while maintaining high spatial resolution for deep tissue observations. The spectrally distinct absorption of visible and near-infrared photons by endogenous tissue chromophores facilitates extraction of diverse anatomic, functional, molecular, and metabolic information from living tissues across various scales, from organelles and cells to whole organs and organisms. The primarily blood-related contrast and limited penetration depth of OA imaging have fostered the development of multimodal approaches to fully exploit the unique advantages and complementarity of the method. We review the recent hybridization efforts, including multimodal combinations of OA with ultrasound, fluorescence, optical coherence tomography, Raman scattering microscopy and magnetic resonance imaging as well as ionizing methods, such as X-ray computed tomography, single-photon-emission computed tomography and positron emission tomography. Considering that most molecules absorb light across a broad range of the electromagnetic spectrum, the OA interrogations can be extended to a large number of exogenously administered small molecules, particulate agents, and genetically encoded labels. This unique property further makes contrast moieties used in other imaging modalities amenable for OA sensing.
Topics: Photoacoustic Techniques; Humans; Contrast Media; Animals; Multimodal Imaging; Magnetic Resonance Imaging
PubMed: 38738633
DOI: 10.1039/d3cs00565h -
The British Journal of Radiology Sep 2020Functional imaging tools have emerged in the last few decades and are increasingly used to assess the function of the human heart . Positron emission tomography (PET) is... (Review)
Review
Functional imaging tools have emerged in the last few decades and are increasingly used to assess the function of the human heart . Positron emission tomography (PET) is used to evaluate myocardial metabolism and blood flow. Magnetic resonance imaging (MRI) is an essential tool for morphological and functional evaluation of the heart. In cardiology, PET is successfully combined with CT for hybrid cardiac imaging. The effective integration of two imaging modalities allows simultaneous data acquisition combining functional, structural and molecular imaging. After PET/CT has been successfully accepted for clinical practices, hybrid PET/MRI is launched. This review elaborates the current evidence of PET/MRI in cardiovascular imaging and its expected clinical applications for a comprehensive assessment of cardiovascular diseases while highlighting the advantages and limitations of this hybrid imaging approach.
Topics: Heart Diseases; Heart Neoplasms; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Myocardial Ischemia; Organ Motion; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed
PubMed: 32023123
DOI: 10.1259/bjr.20190836 -
Recent Results in Cancer Research.... 2020Molecular imaging with positron emission tomography (PET) using tumour-seeking radiopharmaceuticals has gained wide acceptance in oncology with many clinical... (Review)
Review
Molecular imaging with positron emission tomography (PET) using tumour-seeking radiopharmaceuticals has gained wide acceptance in oncology with many clinical applications. The hybrid imaging modality PET/CT (computed tomography) allows assessing molecular as well as morphologic information at the same time. Therefore, PET/CT represents an efficient tool for whole-body staging and re-staging within one imaging modality. In oncology, the glucose analogue 18-F-fluorodeoxyglucose (FDG) is the most widely used PET/CT radiopharmaceutical in clinical routine. FDG PET and FDG PET/CT have been used for staging and re-staging of tumour patients in numerous studies. This chapter will discuss the use and the main indications of FDG PET/CT in oncology with special emphasis on lung cancer, lymphoma, head and neck cancer, melanoma and breast cancer (among other tumour entities). A review of the current literature is given with respect to primary diagnosis, staging and diagnosis of recurrent disease. Besides its integral role in diagnosis, staging and re-staging of disease in oncology, there is increasing evidence that FDG PET/CT can be used for therapy response assessment (possibly influencing therapeutic management and treatment planning) by evaluating tumour control, which will also be discussed in this chapter.
Topics: Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Staging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals
PubMed: 32594401
DOI: 10.1007/978-3-030-42618-7_19 -
Handbook of Experimental Pharmacology 2023Biomedical imaging is a powerful tool for medical diagnostics and personalized medicines. Examples of commonly used imaging modalities include Positron Emission...
Biomedical imaging is a powerful tool for medical diagnostics and personalized medicines. Examples of commonly used imaging modalities include Positron Emission Tomography (PET), Ultrasound (US), Single Photon Emission Computed Tomography (SPECT), and hybrid imaging. By combining these modalities, scientists can gain a comprehensive view and better understand physiology and pathology at the preclinical, clinical, and multiscale levels. This can aid in the accuracy of medical diagnoses and treatment decisions. Moreover, biomedical imaging allows for evaluating the metabolic, functional, and structural details of living tissues. This can be particularly useful for the early diagnosis of diseases such as cancer and for the application of personalized medicines. In the case of hybrid imaging, two or more modalities are combined to produce a high-resolution image with enhanced sensitivity and specificity. This can significantly improve the accuracy of diagnosis and offer more detailed treatment plans. In this book chapter, we showcase how continued advancements in biomedical imaging technology can potentially revolutionize medical diagnostics and personalized medicine.
Topics: Humans; Precision Medicine; Tomography, Emission-Computed, Single-Photon; Positron-Emission Tomography; Multimodal Imaging; Sensitivity and Specificity
PubMed: 36907970
DOI: 10.1007/164_2023_641 -
Current Treatment Options in Oncology Jul 2020Neuroendocrine tumors (NETs) can occur in a wide variety of organs and display a spectrum of pathologic behavior. Accurate and effective imaging is paramount to the... (Review)
Review
Neuroendocrine tumors (NETs) can occur in a wide variety of organs and display a spectrum of pathologic behavior. Accurate and effective imaging is paramount to the diagnosis, staging, therapy, and surveillance of patients with NET. There have been continuous advancements in the imaging of NET which includes anatomic and functional techniques.
Topics: Diagnostic Imaging; Humans; Multimodal Imaging; Neoplasm Staging; Neuroendocrine Tumors; Organ Specificity; Outcome Assessment, Health Care; Radiopharmaceuticals
PubMed: 32728967
DOI: 10.1007/s11864-020-00770-8